Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated 54 enrolled University of Michigan Rogel Cancer Center Pfizer · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, blinded, placebo-controlled study evaluating the drug, SUO11248 (SUTENT), for maintenance therapy in advanced urothelial cancer.

Timeline

Start: 2006-05
Primary completion: 2011-12
Completion: 2012-12

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Publications

Results Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 1;120(5):692-701. doi: 10.1002/cncr.28477. Epub 2013 Nov 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Sunitinib	Small molecule	50 mg	Oral